Page 51 - 2022_01-Haematologica-web

Marginal zone lymphoma
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. Hematol Oncol. 2017;35(4):536-541.
55. Arcaini L, Rossi D, Paulli M. Splenic margin- al zone lymphoma: from genetics to man- agement. Blood. 2016;127(17):2072-2081.
56. Kalpadakis C, Pangalis GA, Angelopoulou MK, Vassilakopoulos TP. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1-2):139-148.
57. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209 (9):1537-1551.
58. Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contri- bution of MYD88 testing. Virchows Arch. 2016;468(3):259-275.
59. Santos TSd, Tavares RS, Farias DLCd. Splenic marginal zone lymphoma: a litera- ture review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter. 2017;39(2):146-154.
60. Piris MA, Onaindia A, Mollejo M. Splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1-2):56-64.
61. Flinn I, van der Jagt R, Chang JE, et al. First- line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2017;35(15 suppl): 7500.
62. Rummel MJ, Koenigsmann M, Chow KU, et al. Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, random- ized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2018;36(15 suppl):7515.
63. Kalpadakis C, Pangalis GA, Sachanas S, et al. Rituximab monotherapy in splenic mar- ginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666-670.
64. Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreat- ment trial for low tumour burden non-fol- licular indolent B-cell non-Hodgkin lym- phomas: Eastern Cooperative Oncology Group protocol E4402. Br J Haematol. 2016;173(6):867-875.
65. Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94(5):585-596.
66.Hsu A, Kurt H, Zayac AS, Olszewski AJ. CD5 expression in marginal zone lym- phoma predicts differential response to rit- uximab or bendamustine/rituximab. Leuk Lymphoma. 2021 Sep 1. [Epub ahead of print]
67. Bastidas-Mora G, Bea S, Navarro A, et al. Clinico-biological features and outcome of patients with splenic marginal zone lym- phoma with histological transformation. Br J Haematol. 2021 Sep 14. [Epub ahead of print]
68. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation,
69.
staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma propos- als for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
marginal zone lymphoma: preliminary results from an open label, phase II study. Blood. 2019;134(Suppl_1):3999.
83.Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next- generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lym- phoma. Clin Cancer Res. 2021 Sep 15. [Epub ahead of print]
70. Copie-Bergman C, Gaulard P, Lavergne- Slove A, et al. Proposal for a new histologi- cal grading system for post-treatment eval- uation of gastric MALT lymphoma. Gut. 2003;52(11):1656.
71. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial. Blood. 2017;130 (12):1409-1417.
72.Montalban C, Abraira V, Arcaini L, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point- based score for practical use. Leuk Lymphoma. 2014;55(4):929-931.
73. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prog- nostic model for clinical use. Blood. 2006;107(12):4643-4649.
74. Conconi A, Thieblemont C, Cascione L, et al. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica. 2020;105(11):2592-2597.
75. Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extra- nodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16(3):473-480.
76. Albano D, Borghesi A, Bosio G, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma: (18)F-FDG PET/CT and CT findings in 28 patients. Br J Radiol. 2017;90(1079):20170311.
77. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distin- guishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21):4643-4651.
78. Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scan- ning similar to diffuse large B-cell lym- phoma (DLBCL). Ann Oncol. 2009;20 (3):508-512.
79. Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibru- tinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16): 2224- 2232.
80.Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lym- phoma: long-term follow-up and biomark- er analysis. Blood Adv. 2020;4(22): 5773- 5784.
81. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non- Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826-833.
82. Handunnetti SM, Khot A, Anderson MA, et al. Safety and efficacy of ibrutinib in com- bination with venetoclax in patients with
84.
85.
Gopal AK, Kahl BS, de Vos S, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
Martin P, Armas A, Gopal AK, et al. Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL). Blood. 2015;126(23):1543.
86. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357-3359.
87. Gilead Sciences Inc. Idelalisib Urgent Safety Letter. 2016.
88. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes fre- quent immune-mediated hepatotoxicity. Blood. 2016;128(2):195-203.
89. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898- 3905.
90. Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv. 2021;5(3):823-828.
91. Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kd/CK1e inhibitor in patients with relapsed or refractory indo- lent lymphoma. J Clin Oncol. 2021;39(15): 1609-1618.
92.Phillips TJ, Corradini P, Gurion R, et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lym- phoma (CITADEL-204). Blood. 2020;136 (Suppl 1):27-28.
93.
94.
95.
96.
Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020;136(Suppl 1):40-41.
Leonard JP, Jung S-H, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lym- phoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635-3640.
Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open- label, phase 2 trial. Lancet Oncol. 2014;15(12):1311-1318.
Becnel MR, Nastoupil LJ, Samaniego F, et al. Lenalidomide plus rituximab (R(2) ) in pre- viously untreated marginal zone lym- phoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874-882.
haematologica | 2022; 107(1)
43